Rybelsus (semaglutide)

Rybelsus is a prescription oral medication utilized for the treatment of type 2 diabetes, containing the active ingredient semaglutide. It represents a significant medical innovation as it is the first GLP-1 receptor agonist available in pill form, providing an alternative to traditional injectable treatments. The product is developed and manufactured by the Danish pharmaceutical giant Novo Nordisk.

Originally founded in Denmark, Novo Nordisk has grown into a world leader in diabetes care. The brand's origin is tied to the merger of two Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. Today, Rybelsus is primarily produced in Novo Nordisk's advanced manufacturing facilities in Denmark before being distributed globally. The brand is owned by Novo Nordisk A/S, which remains headquartered in Denmark and is controlled by the Novo Nordisk Foundation.